| scholarly article | Q13442814 |
| P50 | author | Jack Cuzick | Q21005493 |
| Xavier Castellsagué | Q28919226 | ||
| Philip E. Castle | Q90438073 | ||
| Lauri E Markowitz | Q96186181 | ||
| Maura L. Gillison | Q107015339 | ||
| Lynette A Denny | Q114454407 | ||
| Eduardo L. Franco | Q39669535 | ||
| Marc Steben | Q42172208 | ||
| Silvia de Sanjosé | Q47367042 | ||
| Marc Arbyn | Q51773680 | ||
| Ginesa Albero | Q56154047 | ||
| Francesc Xavier Bosch José | Q56376448 | ||
| Mireia Díaz | Q56438318 | ||
| Maria Brotons | Q57161162 | ||
| Peter Stern | Q66985993 | ||
| Mark Schiffman | Q69142146 | ||
| Karen Canfell | Q70389126 | ||
| Laia Alemany Perez | Q77862279 | ||
| Anna-Barbara Moscicki | Q87663088 | ||
| Rengaswamy Sankaranarayanan | Q88013761 | ||
| John Doorbar | Q88047207 | ||
| Margaret Stanley | Q88958740 | ||
| Chris J L M Meijer | Q90379336 | ||
| P2093 | author name string | John T Schiller | |
| David Forman | |||
| Jane J Kim | |||
| Mario Poljak | |||
| Thomas R Broker | |||
| William A Fisher | |||
| Mark A Kane | |||
| Authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012 | |||
| P2860 | cites work | Human papillomavirus and cancer prevention: gaps in knowledge and prospects for research, policy, and advocacy | Q26995703 |
| Therapy of human papillomavirus-related disease | Q27007473 | ||
| A review of clinical trials of human papillomavirus prophylactic vaccines | Q36259403 | ||
| Updating the natural history of human papillomavirus and anogenital cancers | Q36979148 | ||
| Modeling preventative strategies against human papillomavirus-related disease in developed countries | Q37198208 | ||
| Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases | Q38064056 | ||
| Nucleic acid tests for the detection of alpha human papillomaviruses | Q38064057 | ||
| New technologies and procedures for cervical cancer screening | Q38064058 | ||
| Introduction of human papillomavirus DNA screening in the world: 15 years of experience | Q38064059 | ||
| Global burden of human papillomavirus and related diseases. | Q38064060 | ||
| Human papillomavirus vaccine introduction--the first five years | Q38064062 | ||
| Understanding human papillomavirus vaccine uptake | Q38064063 | ||
| Human papillomavirus, human immunodeficiency virus and immunosuppression | Q38064064 | ||
| Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries | Q38064065 | ||
| Implementation of human papillomavirus immunization in the developing world | Q38064066 | ||
| Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis | Q38064067 | ||
| The biology and life-cycle of human papillomaviruses. | Q38064068 | ||
| Human papillomavirus vaccines--immune responses | Q38064069 | ||
| Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer | Q38064070 | ||
| Global prevention and management of human papillomavirus related diseases: the pressing challenges and the compelling opportunities. Foreword | Q85582381 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Papillomavirus infections | Q104205912 |
| P304 | page(s) | I1-31 | |
| P577 | publication date | 2013-11-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Comprehensive control of human papillomavirus infections and related diseases | |
| P478 | volume | 31 Suppl 8 |
| Q36106799 | A Bivariate Mixture Model for Natural Antibody Levels to Human Papillomavirus Types 16 and 18: Baseline Estimates for Monitoring the Herd Effects of Immunization |
| Q57148888 | Association between Human Papillomavirus and Non-cervical Genital Cancers in Brazil: A Systematic Review and Meta-Analysis |
| Q35962518 | Candidate Soluble Immune Mediators in Young Women with High-Risk Human Papillomavirus Infection: High Expression of Chemokines Promoting Angiogenesis and Cell Proliferation. |
| Q41692280 | Cervical cancer in low and middle income countries: Addressing barriers to radiotherapy delivery |
| Q36602973 | Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study |
| Q47765039 | Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain |
| Q36656025 | Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1. |
| Q89933773 | Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer |
| Q34275134 | Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine |
| Q34442828 | HPV associated tumor cells control tumor microenvironment and leukocytosis in experimental models |
| Q92938795 | HPV infections and flat penile lesions of the penis in men who have sex with men |
| Q41096629 | High-risk Oncogenic Human Papilloma Virus Infection of the Foreskin and Microbiology of Smegma in Prepubertal Boys. |
| Q93332482 | Human Papillomavirus Subtype 16 and the Pathologic Characteristics of Laryngeal Cancer |
| Q33752967 | Human papilloma virus E7 oncoprotein abrogates the p53-p21-DREAM pathway |
| Q55175761 | Human papilloma virus: global research architecture assessed by density-equalizing mapping. |
| Q34411665 | Impact of soy isoflavones on the epigenome in cancer prevention. |
| Q90599827 | Incidence and mortality due to cervical cancer in 4 south European countries |
| Q90669279 | Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration |
| Q37135074 | Less than 3 doses of the HPV vaccine - Review of efficacy against virological and disease end points |
| Q41933591 | Modeling of US Human Papillomavirus (HPV) Seroprevalence by Age and Sexual Behavior Indicates an Increasing Trend of HPV Infection Following the Sexual Revolution |
| Q40483309 | Nomenclature of squamous cell precursor lesions of the lower female genital tract : Current aspects |
| Q47141407 | Prevalence of oncogenic human papillomavirus genotypes in patients diagnosed with anogenital malignancies in Botswana |
| Q26782255 | Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer |
| Q38388049 | Reliable detection of human papillomavirus in recurrent laryngeal papillomatosis and associated carcinoma of archival tissue |
| Q36714717 | Role of vaccination in the sustainability of healthcare systems |
| Q42245288 | Searching for the initiating site of the major capsid protein to generate virus-like particles for a novel laboratory mouse papillomavirus |
| Q92619054 | Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis |
| Q38253253 | Site of infections associated with human papillomavirus |
| Q35811067 | Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM |
| Q35568922 | Systematic review of model-based cervical screening evaluations |
| Q94407769 | The Economic Value of Vaccination: Why Prevention is Wealth |
| Q61816899 | The Situation of Cervical Cancers in the Context of Female Genital Cancer Clustering and Burden of Disease in Arad County, Romania |
| Q50988785 | Therapeutic cancer vaccines. |
| Q39020098 | Vaccine strategies: Optimising outcomes |
| Q89955986 | Vaginal Suppositories Containing Sheta2 To Treat Cervical Dysplasia: Pharmacokinetics Of Daily Doses And Preliminary Safety Profile |
Search more.